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Protein glycosylation, as an important post-translational modification, is implicated in a number of ailments. Applying
proteomic approaches, including mass spectrometry (MS) analyses that have played a significant role in biomarker
detection and early diagnosis of diseases, to the study of glycoproteins or glycopeptides will facilitate a deeper
understanding of many physiological functions and biological pathways involved in cancer, inflammatory and
degenerative diseases. The abundance of glycopeptides and their ionization potential are relatively lower compared to
those of non-glycopeptides; therefore, sample enrichment is necessary for glycopeptides prior to MS analysis. The
application of nanotechnology in the past decade has been rapidly penetrating into many diverse scientific research
disciplines. Particularly in what we now refer to as the “glycoproteomics area”, nanotechnologies have enabled
enhanced sensitivity and specificity of glycopeptide detection in complex biological fluids, which are critical for disease
diagnosis and monitoring. In this review, we highlight some recent studies that combine the capabilities of specific
nanotechnologies with the comprehensive features of glycoproteomics. In particular, we focus on the ways in which
nanotechnology has facilitated the detection of glycopeptides in complex biological samples and enhanced their
characterization by MS, in terms of intensity and resolution. These studies reveal an increasingly important role for
nanotechnology in helping to overcome certain technical challenges in biomarker discovery, in general, and
glycoproteomics research, in particular.Introduction
Protein glycosylation is one of the most common post-
translational modifications (PTMs) in living cells [1,2].
Glycoproteins play a vital role in biological processes
including cell adhesion, receptor activation, and signal
transduction [3-5]. As such, altered or erroneous glyco-
sylation is often associated with inflammatory diseases,
neurodegenerative disorders, and even certain cancers
[6,7]. For example, several investigators have observed
that the abnormal expression of different glycosylated
proteins were implicated in disease and that changes in
the level of glycoprotein could be used as hallmarks for
disease diagnosis, including the carbohydrate antigen CA-
19-9 for colon cancer [8], the prostate-specific antigen
(PSA) for prostate cancer [9], α-fetoprotein for liver cancer
[10], and β-human chorionic gonadotropin for germ cell
tumors [11]. Furthermore, many accessible, membrane-
bound or extracellular proteins are glycosylated and could* Correspondence: yhu@houstonmethodist.org
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tor for breast cancer therapy [12].
Thus far, analytical methods of identifying (sometimes
subtle) changes in disease-relevant glycoproteins can be di-
vided into two main groups: glycoprotein- or glycopeptide-
based analysis. We illustrate the workflow of these two
approaches in Figure 1 [1]. In the first (glycoprotein-based)
approach, glycoproteins are enriched by different separation
methods, such as size exclusion, ion exchange, affinity chro-
matography, chemical immobilization, and other methods.
To identify the protein part of a glycoprotein is much easier
than to identify the glycan part of the same glycoprotein. In
the latter (glycopeptide-based) strategy, the glycoproteins
initially undergo enzymatic or chemical degradation, and
the resulting glycopeptides can be enriched by several
methods, such as lectin-affinity chromatography [13-15],
boronic acid-based approach [16,17], hydrazide chemistry
[18-20], or solid-phase extraction using hydrophilic interac-
tions [21]. The enriched glycopeptides are then deglycosyl-
ated and quantified via MS analysis. Consequently, the
sequences of various glycopeptides and their specific glyco-
sylation sites can be easily identified. With the advent of
ever more sophisticated MS modalities, we can now delve
even deeper in the realm of glycoproteomics research. Still,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Typical workflow for glycoproteomics analyses [1].
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samples (e.g., serum or blood) using current MS-based
techniques, because the proportion of glycopeptides in
total solution is quite small, and their signals in MS
profiles are often obscured by those of non-glycosylated
peptides [22]. Therefore, enhancing the specificity and
sensitivity of glycopeptide enrichment and detection in
complex samples remains a very real challenge.
In the past decade, we have witnessed an enormous
growth in the application of nanotechnology to solve bio-
logical and biomedical problems. Due to some of these
(nano) technological advances, we can now identify and
analyze biomolecules at a speed and resolution never seen
before. Compared to conventional macro-scale materials,
nano materials, such as nanoparticles, nanowires, nano-
tubes, nanorods, and thin films with meso-scale pores,
have unique transport properties (i.e., more efficient
electron transport), better optical excitation and high
detection efficiency. Nanomaterials also impart to their
fabricated platforms higher surface-to-volume ratio with
reduced dimensionality, which are key features that often
enhance the physical and chemical properties of materials.
In addition, materials with lower dimensionality are
conducive to extremely high unit-density integration on
arrays and lab-on-a-chip platforms for point-of-care
devices for high-throughput biodetection. Miniaturized
devices composed of nanomaterials have the advantage of
low cost, good portability, and potential use in minimally
invasive instrumentation [23]. In Figure 2, we present
some examples of nanomaterial-enabled platforms for bio-
molecule detection, such as silicon nanowire field-effecttransistor (SiNW-FET) sensors for detecting prostate-
specific antigen (PSA), Real-time Quartz Crystal Micro-
balance (QCM) for detecting serum proteins and ZnO
nanorod platforms for detecting protein interaction. We
and others have developed a series of mesoporous silica
thin film chips with a variety of nanotextures that can
selectively enrich for low molecular weight peptides from
complex biological fluids, as part of a biomarker discovery
platform [24-28].
Glycoproteins are not as amenable to isolation and
identification due confounding factors such as complex
glycan structures, glycan isomers, and amino acid resi-
dues attached to the oligosaccharide chains. The most
commonly employed technique for the analysis of pro-
tein glycosylation (glycosylation site identification, gly-
can structure determination, site occupancy, and glycan
isoform distribution) is MS, albeit with still a few exist-
ing technical challenges [32]. In this review, we will
highlight some of the platforms that have been deve-
loped for the enrichment of glycopeptides from complex
samples, and introduce emerging combination platforms
that couple the sensitivity and accuracy of MS to the
exquisite selectivity of nano-platforms.
Different nano-platforms used to enrich
glycopeptides
A nanomaterial is a natural, incidental or manufactured
material containing particles in an unbound, aggregate or
agglomerate state, where one or more external dimensions
is in the size range 1–100 nanometers. Due to their smaller
size, nanomaterials possess incredibly larger surface areas
Figure 2 (See legend on next page.)
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Figure 2 Examples of nano-dimensioned biosensors. (a) SiNW FET sensors are used to detect prostate-specific antigen (PSA) [29]; (b) Real-time
Quartz Crystal Microbalance (QCM) and electrical sensing of model proteins [30]; and (c) Enhanced fluorescence detection carried out on various
biological systems coupled to ZnO nanorod platforms. Scanning electron microscopy (panel 1) and fluorescence (panels 2 through 5) images of biotinylated
bovine serum albumin (bBSA) and fluorescein derivativeconjugated streptavidin (DTAF-strept) on ZnO nanorods [31].
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sites for glycopeptide enrichment and unique optical prop-
erties, in the context of rapid and sensitive detection.
Perhaps the most attractive characteristic of nanomaterials
is the degree to which their size, shape and morphology
can be precisely controlled to enhance the optical, elec-
tronic, or magnetic capabilities typically desired in certain
applications. Several nano-platforms exist for the isolation
of glycopeptides in complex samples with improved sensi-
tivity and specificity, and we discuss them in more details
in the following Subsections.
Nanoparticles for glycopeptide enrichment
Nanoparticles are arguably the most widely used nanoma-
terial to assemble chips for biomolecule enrichment be-
cause: 1) nanoparticles can be synthesized with various size
distributions, and morphologies; 2) nanoparticles can be
modified and diversified by numerous reagents for specific
uses; and 3) they exhibit unique optical and electrochem-
ical features. When attempting to enrich glycopeptides in
complex samples, researchers often adopt core-shell struc-
tured nanoparticles with a magnetic core within a thin
layer of compatible material. The magnetic core, which
provides a strong magnetic force, would be simply
attracted by magnets and the outer layer would be easily
modified by various organic or inorganic reagents to
recognize the biomarker of interest.
Using a version of the above approach, Zhou et al. fabri-
cated aminophenyl boronic acid-functionalized magnetic
nanoparticles and used them to selectively capture glyco-
peptides and glycoproteins from mixtures containing non-
glycomoleculars [33]. Other groups have also applied
versions of surface-modified nanoparticles for glycopro-
tein selection. For example, 3-aminopropyltriethoxysilane
(APTES) is frequently used as a surface-modifying reagent
for silica nanoparticles, whereby the amino group imparts
a positive charge. Zhang Y. and coworkers designed a
one-step salinization reaction to assemble APTES onto
the nanoparticle surface in order to capture aldehyde
groups on oxidized glycopeptides. These nanoparticles
greatly reduced the coupling time from 12–16 hours to
just 4 hours without sacrificing enrichment efficiency,
compared to traditional solid-phase extraction methods
based on hydrazide resins [34]. Zhang L. et al. developed a
novel composite material with a core-satellite structure.
These are gold nanoparticles, functionalized with boronic
acid, and then anchored on the surface of the silica-coated
magnetic core. Using this strategy, the investigators wereable to recover 85.9% of glycopeptides and 71.6% of glyco-
proteins after enrichment. The composite nanoparticles had
an adsorption capacity of more than 79 mg of glycoproteins
per gram of the material. The investigators used these new
composite nanoparticles to enrich glycosylated proteins
from human colorectal cancer tissues for subsequent identi-
fication of N-glycosylation sites. They were able to map 194
unique glycosylation sites, of which 165 sites (85.1%) were
newly identified, to 155 different glycoproteins [35].
Polysaccharides can also be used as a surface-modifying
component for glycopeptide enrichment. Xiong et al.
reported a layer-by-layer approach to synthesize magnetic
nanoparticles (MNPs) that are coated with multilayered
polysaccharide shells, and then used these hydrophilic
materials for selective enrichment of glycopeptides from
biological samples. These investigators identified 605
unique N-glycosylation sites in 616 distinct glycopeptides,
corresponding to 350 glycosylated proteins in 20 μg mouse
liver protein sample. Their results indicated that exploiting
specific sugar-sugar interactions shows promise as a design
strategy for characterizing protein glycosylation [36].
Rather than using boronic acid as a surface-modifying
reagent for nanoparticles, Tran et al. developed a new
kind of gold nanoparticles, functionalized with ultra-
small hydrazide groups, with a core diameter of 1.2 nm.
The assembly process involves an oxidation step and
covalent coupling, whereby the carbohydrate moiety of
the glycoproteins are oxidized into aldehydes by periodate
and the oxidized glycoproteins are covalently coupled to
hydrazide resin. No glycoproteins are removed by wash-
ing. They successfully utilized these nanoparticles to iso-
late 90% of the glycopeptides from complex biological
samples. The nanoparticle stability in biological solution,
unique solubility, and large capacity for peptide capturing
provide great application potential in glycoproteomics
studies [37].
Isolating glycopeptides via their lectin moiety is another
common approach, and commercialized solutions are
now available in the market. Tsutsumi and colleagues con-
jugated gold nanoparticles (GNPs) with monosaccharide-
modified peptides as optical probes for lectin detection.
The aggregation of the glycopeptide-modified GNPs with
concanavalin A (ConA) causes an absorption shift from
534 nm to 620 nm, an apparent color change that can be
detected by the naked eye [38].
Ligand-modified nanoparticles have been proven to be
an excellent platform for glycopeptide enrichment, but
ligand-free nanoparticles are emerging as good candidates
Figure 3 (See legend on next page.)
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Figure 3 A schematic of glycopeptide enrichment from dilute solutions using mesoporous silica material modified with boronic acid.
The pores act as a nanoreactor for the specific binding of di-boronic acid groups to glycopeptides (top half of the figure). FE-SEM images of
boronic acid-modified mesoporous silica material at low magnification (a) and the high-resolution image of the squared area in part a; and
(b) TEM images along the vertical direction of the mesoporous materials (c,d) [41].
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group in Fudan University developed ligand-free silver
nanoparticles coated with magnetic nanoarchitecture for
selective enrichment of glycopeptides by taking advantage
of the reversible interaction of glycans with silver nano-
particles. The investigators could easily and quickly (only
1 min incubation time) extract glycopeptides at a low
molar ratio of glycopeptides: non-glycopeptides (1:100)
using these silver-nanoparticle magnetic beads. Moreover,
they mapped 127 unique glycopeptides mapped to 51 dif-
ferent glycoproteins from a very small sample volume
(only 1 μL rat serum) [39].
Particle-based materials are the most widely adopted
for isolating and separating glycosylated peptides due to
their nano dimensionality, tightly controlled size, and
unique optical and electrochemical properties. They will
likely continue to play a prominent role in glyco-
proteomics for biomarker detection and early diagnosis
of diseases.
Mesoporous materials for glycopeptide enrichment
Several classes of porous materials exist and group
according to size. The International Union of Pure and
Applied Chemistry (IUPAC) clarifies [40], microporous
materials and macroporous materials as having pore
diameters less than 2 nm and greater than 50 nm,
respectively; mesoporous materials place in the middle.
Developed since the 1970’s, mesoporous silica materials
are, at present, widely used in drug delivery, imaging,
biosensors, for example, owing to their regular pore
arrangement, simple preparatory methods, and low cost.
Under the influence of strong capillary forces, biomole-
cules entering the mesoporous pores encounter more
activation sites for binding, resulting in higher separ-
ation efficiency. Many glycoproteomics studies have
been conducted using mesoporous materials for glyco-
peptide isolation and separation.
Xu and colleagues first introduced mesoporous silica ma-
terials functionalized with boronic acid for the detection of
glycosylated peptides. In Figure 3, we illustrate the basic
workflow of this approach. The field emission electron
scanning microscope images of the prepared products
show a pattern of regular honeycomb-like hexagonal-
patterned pores. Glycopeptides in solution bound with
high affinity to the groups attached within the pores, mark-
edly improving the solute detection limit [41]. Similarly,
Liu et al. [22] and Zhang H. et al. [42] applied mesoporous
silica functionalized with aminophenylboronic acid (APB)to analyze glycopeptides in standard protein solutions and
rat serum, respectively.
Other than boronic acid, transition metal oxides can be
coupled to mesoporous silica, as demonstrated by Wan
and coworkers. These investigators coated mesoporous
silica microspheres in a layer of zirconium dioxide to cre-
ate a platform for hydrophilic interaction liquid chroma-
tography (HILIC) solid phase extraction (SPE) (depicted in
Figure 4). HILIC has broad glycan specificity, good repro-
ducibility, and compatibility with MS analysis. ZrO2
species were highly dispersed on the surface of meso-
structured cellular foam. Hydrogen bonding between the
oxygen atoms of ZrO2 and the hydrogen atoms of glycans
forms a relatively strong interaction, thus isolating the
glycopeptides from complex samples. Since ZrO2 can also
attract phosphopeptides, the investigators treated digested
mixtures of the phosphoprotein, α-casein, and IgG with
ZrO2/MPS HILIC SPE materials. The results demonstrated
that glycopeptides could be effectively enriched with inter-
ference from Zirconia layer coated silica surface [43].
Oxidized mesoporous carbon is another very useful ma-
terial in glycoproteomics research because of its extraordin-
ary hydrophilicity. Hence, oligosaccharides on N-linked
glycans interact with the carbon functional groups, enab-
ling glycopeptide separation prior to profiling by MS. Using
this approach, Qin et al. enriched N-linked glycans using
oxidized and ordered mesoporous carbon materials of
CMK-3 before matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) MS. Twenty four N-linked
glycans derived from standard glycoproteins could be
detected with high signal-to-noise (S/N) ratios and peak
intensities. Thirty-two N-linked glycans were profiled in
complex samples, five (4 core-fucosylated glycans) of which
exhibited distinct patterns in liver cancer compared to
healthy samples. Their results support the notion that
precisely-sized mesoporous carbon materials could play a
prominent role in clinical glycoproteomics [44].
With such broad applicability and adaptability, we ex-
pect the use of mesoporous materials to continue leaving
an impact on the glycoproteomics landscape. The large
specific surface area, surface modification potential, size
exclusion toward large molecular weight biomolecules,
and support strong capillary force in nano scale are all
characteristics that lend well to their wide-spread use.
Other nano platforms for glycopeptide enrichment
Two-dimensional (2D) crystalline materials have recently
been identified and analyzed for use in glycopeptide
Figure 4 A schematic representation of glycopeptide isolation using mesoporous silica microspheres coated with zirconia [43].
Figure 5 Using functionalized graphene for glycan separation [46].
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layer of carbon, is the first applied in this new class of
materials. A number of unique properties make it inter-
esting and suitable for both fundamental research and
future applications. Due to its large specific area and
ultra-strong absorbability, surface-functionalized gra-
phene or graphene oxide is now used for glycan enrich-
ment. Zhang et al. recently introduced a rapid, highly
efficient, and visual approach for glycan enrichment
using 1-pyrenebutyryl chloride functionalized graphene
oxide [46], illustrated in Figure 5. First, graphene was
functionalized by 1-pyrenebutyric acid and following 1-
pyrenebutyryl chloride treatment. Reversible covalent
bonding occurs between the hydroxyl groups of the gly-
cans and the acyl chloride groups on graphene oxide
via the π-π stacking of 1-pyrenebutyryl chloride. En-
richment efficiency was much improved by the large
specific surface area and heavy functionalization of ac-
tive 1-pyrenebutyryl chloride. When the investigators
tested this material in several sample processing appli-
cations, MS signal intensity, signal-to-noise ratio, and
the number of glycoforms identified on standard oligo-
saccharides or the N-glycans that were released from
glycoproteins increased remarkably.
Carbon nanotubes (CNTs) are allotropes of carbon
exhibiting a cylindrical nanostructure. These cylindrical
carbon molecules have unusual properties that could be,
and is currently, exploited by the electronics industry,
optics industry, and other fields of materials science and
technology. Zhang X. and colleagues constructed a novel
lectin-based electrochemical biosensor of functionalized,
multi-walled CNTs to capture glycans from living cells
[47]. They fabricated the biosensor by adsorbing poly
(diallyldimethylammonium chloride) (PDDA)-function-
alized CNTs (PDCNTs) onto a glassy carbon electrode
(GCE), followed by glutathione (GSH)-protected gold
nanoparticles (AuNPs) adsorption. The resulting material
becomes an effective platform for lectin immobilization,
with high stability and bioactivity. The investigators also
synthesized a thiol-derivatized carbohydrate (thiomanno-
syl dimer) to construct (CNT/thionine/Au–S–mannose)
biocomposites, which used CNTs as carriers to load
enormous amounts of thionine (to generate an electro-
chemical signal) and AuNPs (to anchor the thiomanno-
syl dimer).
The two applications for functionalized CNTs, whether
as a biosensing platform and biocomposite, allow en-
hanced glycan signal detection. The former (electro-
chemical biosensor) has demonstrated good analytical
performance – high sensitivity, selectivity and rapid re-
sponse – for the analysis of mannose in human lung
cancer cells. This approach could be adapted for other
indications by broadening the selection moiety (e.g.,
lectins) for biosensor development.Conclusion and perspective
Investigators have long recognized the significance of
protein glycosylation in physiological processes and dis-
ease, as evidenced by the number of related publications
that continue to accumulate. Furthermore, glycosylated
proteins are increasing identified as biomarkers for early
disease detection of diseases via proteomics methods.
Although recent advances in mass spectrometry have
made large-scale identification of proteins feasible, it is
still very challenging to analyze protein glycosylation in
complex samples owing to the fact that glycopeptides
often constitute a minor portion of the total peptide
mixture, whose signal intensities are often lower com-
pared to non-glycosylated peptides and are suppressed
in the presence of non-glycopeptides. Nanotechnology
has undoubtedly contributed to the realization of glyco-
protein/glycopeptide enrichment methods, particularly
from enrichment from complex samples in preparation
for MS characterization. The use of nanomaterials with
various morphologies and characteristics (nanoparticles,
mesoporous materials, nanosheets, nanotubes, etc.) has
enabled enhanced sensitivity and specificity of glycopep-
tides isolation.
Challenges do remain in detecting post-translationally
modified proteins/peptides, especially circulating glyco-
peptides. Characterizing glycosylated peptides is also diffi-
cult due to unique electrochemical properties, optical
properties, and energy brand structure. By applying nano-
scaled materials to tunable platforms, scientists have
greatly enhanced the capabilities of traditional MS-based
techniques, by increasing mass resolution, mass range,
mass intensities, to name a few. We believe this significant
progress blazes a trail for future efforts (and accomplish-
ments) in the combined areas of nano-engineering, MS
and glycoproteomics.
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